EMEA-002594-PIP02-20

Table of contents

Key facts

Active substance
Infigratinib
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0331/2021
PIP number
EMEA-002594-PIP02-20
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Treatment of achondroplasia
Route(s) of administration
Oral use
Contact for public enquiries
QED Therapeutics Inc.

E-mail: info@qedtx.com
Tel: +1 65202314088

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating